BCM
VERA icon

Bayesian Capital Management’s Vera Therapeutics VERA Stock Holding History

Bayesian Capital Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,722
Closed -$518K – 1014
2024
Q3 		$518K Buy
+11,722
New +$445K 0.06% 368
2024
Q2 		– Sell
-13,422
Closed -$579K – 1116
2024
Q1 		$579K Buy
+13,422
New +$478K 0.06% 405

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Bayesian Capital Management's VERA Position: Q4 2024 in Review

Bayesian Capital Management sold out of Vera Therapeutics (VERA) in Q4 2024, closing a stake of 11,722 shares — an estimated $518K sold.

Bayesian Capital Management first reported a position in VERA in Q1 2024 and held it in 2 quarters. The position peaked at $579K in Q1 2024. 178 funds tracked by Wall St. Rank hold VERA as of Q4 2024.

  • Bayesian Capital Management reported no remaining Vera Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 11,722 Vera Therapeutics shares in Q4 2024, an estimated $518K.
  • Bayesian Capital Management first reported a position in Vera Therapeutics in Q1 2024 and held it in 2 quarters.
  • Bayesian Capital Management's Vera Therapeutics position peaked at $579K in Q1 2024.
  • 178 funds tracked by Wall St. Rank held Vera Therapeutics as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.